Physician profile

Muhammad A Alim

Pulmonary Disease · Bakersfield, CA

NPI 1588619464

$4,101.26

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

See the full distribution for Pulmonary Disease

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,071.36

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $1,664.97 2019-2024 Trelegy Ellipta, Nucala, Arexvy
Astrazeneca Pharmaceuticals LP $767.78 2019-2024 Breztri, Fasenra, Farxiga
Penumbra, INC. $350.59 2021-2022
Janssen Pharmaceuticals, INC $215.73 2021-2024 Xarelto
Boehringer Ingelheim Pharmaceuticals, INC. $213.29 2019-2024 Ofev
Pulmonx Corporation $173.65 2019-2022
Abiomed $131.25 2024 Impella
Intuitive Surgical, INC. $95.37 2023 Da Vinci Surgical System
Pfizer INC. $95.25 2019-2021
Baxter Healthcare $86.87 2023-2024 Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System
Axsome Therapeutics, INC. $54.21 2024 Sunosi
Inspire Medical Systems, INC. $35.79 2024 Inspire
Insmed, INC. $33.04 2021-2022
Novartis Pharmaceuticals Corporation $29.57 2024
Sunovion Pharmaceuticals INC. $27.96 2019
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Regeneron Healthcare Solutions, INC. $24.98 2024 Dupixent
Genzyme Corporation $19.88 2024
Mylan Specialty L.P. $19.61 2022
United Therapeutics Corporation $18.45 2019
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $16.84 2023 Lifevest
Gilead Sciences, INC. $13.68 2022
Circassia INC. $12.50 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Muhammad A Alim

$4,101.26

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/298769/muhammad-a-alim

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.